BioSpace News Archive

Animal osteoporosis treatment is provided to animals in order to regain bone mass and fill in the lesions caused in the matured bones.

The amniotic products market is estimated to observe considerable growth during the forecast period of 2021-2031.

Biomerica, Inc. (Nasdaq: BMRA), (the “Company”) a global provider of advanced medical products, today reported its first quarter fiscal 2022 financial results.

Apellis Pharmaceuticals, Inc. and Swedish Orphan Biovitrum AB announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion recommending the marketing authorization of Aspaveli® for the treatment of adults with paroxysmal nocturnal hemoglobinuria who are anemic after treatment with a C5 inhibitor for at least three months.

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) for active immunization for the prevention of invasive disease and pneumonia caused by Streptococcus pneumoniae in individuals 18 years of age and older.

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, will report financial results for the third quarter 2021 on Thursday, October 28, 2021, following the close of the market.

Bio-Thera Solutions, Ltd. (688177:SH), today announced the company has reached licensing and supply agreements with Pharmapark LLC, for BAT2206, its ustekinumab biosimilar, under which Pharmapark will have exclusive rights to distribute and market the drug with a status of a local product in Russia and other CIS countries.

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion for sacituzumab govitecan as monotherapy indicated for adult patients with unresectable or metastatic triple-negative breast cancer (TNBC) who have received two or more prior systemic therapies, at least one of them for advanced disease.

Sensus Healthcare, Inc. announces that Joseph Sardano, Chairman and Chief Executive Officer and Javier Rampolla, Chief Financial Officer of Sensus Healthcare will participate in a virtual fireside chat hosted by Maxim Group LLC and M-Vest being held Tuesday, October 19, 2021 at 11:00 a.m. ET

Medivir AB (Nasdaq Stockholm: MVIR) today announces that a joint patent application for MALT1 inhibitors submitted together with Rheos Medicines, Inc., a US-based biopharmaceutical company, has been made public.